Major clinical research advances in gynecologic cancer in 2021.

J Gynecol Oncol · 2022 · PMC8899869 · PMID 35245004

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Exploratory PFS analyses in the PD-L1 IC ≥5% subgroup showed a trend toward atezolizumab (PFS: hazard ratio [HR]=0.64, 95% CI=0.43–0.96).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.